Horizon scanning: US FDA approves pomalidomide (Pomalyst®) for advanced multiple myeloma

The objective response rate was 7.4% in the monotherapy arm (median duration of response not yet reached) and 29.2% in the combination group (median duration of response of 7.4 months).   Pomalidomide carries a Boxed Warning alerting patients and healthcare professionals that it should not be used in pregnant women due to a risk of severe life-threatening birth defects, and that it can cause blood clots. It is available only through a Risk Evaluation and Mitigation Strategy (REMS) Program, similar to those in ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news